Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects “minimal” sales this year from its Alzheimer’s treatment initially...
Source: theridgefieldpress.com
📰 Aduhelm News
Page 11 - Aduhelm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aduhelm. Real-time updates on events, politics, business and more.
Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects “minimal” sales this year from its Alzheimer’s treatment initially...
Source: ncadvertiser.com
Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects “minimal” sales this year from its Alzheimer’s treatment initially...
Source: trumbulltimes.com
Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects “minimal” sales this year from its Alzheimer’s treatment initially...
Source: expressnews.com
Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects “minimal” sales this year from its Alzheimer’s treatment initially...
Source: middletownpress.com
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
Cambridge, MA, Jan 28, 2022 - (JCN Newswire) - Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM
Source: finanznachrichten.de
Biogen Inc.: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
CAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa)
Source: finanznachrichten.de
CMS decision to limit Aduhelm coverage could have 'ripple effect' on other potential therapies
This week the US Centers for Medicare & Medicaid Services (CMS) has announced a long-awaited proposal for Aduhelm coverage: proposing it would only cover the recently approved Alzheimer’s Drug for people in qualifying clinical trials. This could have a ripple effect on decisions from private insurers and other potential drugs in the pipeline.
Jayne Hornung Lee Fleisher National Coverage Determination European Medicines Agency Zinsight Technology Medical Officer
Source: biopharma-reporter.com